It's the end of 2012, and that means that it's time to take a look back at the year in retrospect. We'll be reading through the naughty and nice list (we've already checked it twice), and counting down the 25 best-performing stocks, and the 25 worst-performing stocks, in the health-care sector this year.
In this segment, Motley Fool health-care analysts David Williamson and Max Macaluso take a look at #9 on the nice list, Hemispherx BioPharma (NYSEMKT:HEB), and how this company left investors with more than a little something extra in their stockings this year.
David Williamson has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.